ACTRN12612000591853招募中2 期
A multi-centre,single arm, phase II study to evaluate the efficacy of a single weekly 100mg dose of Rituximab over 4 weeks in patients with refractory or relapsing idiopathic thrombocytopaenic purpura
Florence Peterson Fund0 个研究点目标入组 50 人开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Aged over 18 years
- •Refractory ITP defined as a platelet count of <30 despite 8 weeks of standard ITP therapy
- •ITP that has relapsed post splenectomy
排除标准
- •Aged <18 years
- •ITP diagnosed <8 weeks
- •Prior Rituximab therapy
- •HIV infection
- •SLE associated
- •Lymphoproliferative associated
研究者
相似试验
进行中（未招募）
1 期
Research study to determine whether a drug called obinutuzumab given to persons with relapsed and refractory Waldenström Macroglobulinemia in induction therapy followed by two years of maintenance is safe and efficacious.EUCTR2016-005053-20-PLPolish Myeloma Consortium30
进行中（未招募）
1 期
Clinical study aimed to assess in patients with triple-negative operable breast cancer the activity of the drug zoledronate administered before surgery, according to the the tumor aggressiveness (determined by the level of expression of the p53 protein)ewly diagnosed, untreated, operable triple negative breast cancerMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004194-16-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI21
进行中（未招募）
1 期
A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaCytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104CTIS2023-507899-47-00Goethe University Frankfurt40
招募中
不适用
A multicenter, single arm phase 2 study to examine efficacy and cerebrospinal fluid transitivity of Osimertinib in leptomeningeal carcinomatosis (LMC) patients with non-small cell lung cancer harboring EGFR mutatioJPRN-UMIN000023710HANSHI15
进行中（未招募）
1 期
DALY II USA/MB-CART2019.1 for DLBCCTIS2023-508508-39-01Miltenyi Biomedicine GmbH110